Linkedin
Contact us
Linkedin
Contact us

Altreos Research Partners

Clinical Development & Regulatory Support

  • Services

Clinical Development & Regulatory Support

Our team delivers comprehensive medical writing and regulatory documentation to support CNS drug development programs from early Phase 1 through proof-of-concept and beyond. Our writing expertise is fully integrated with study design and execution, ensuring scientific accuracy, regulatory alignment, and consistency across all deliverables.

Capabilities include:

  • Clinical trial protocols and amendments
  • Clinical study reports (CSRs) across Phase 1, 2, and 3
  • Medical writing support in Phase 2 and Phase 3 across numerous CNS indications, including pain, substance use disorder, and mood disorders
  • Regulatory briefing books and meeting materials for interactions with health authorities
  • Clinical efficacy and safety summaries
  • Labeling updates and regulatory submission support

Drug Abuse Potential Assessment (DAPA)

We develop standalone, NDAready Drug Abuse Potential Assessments, integrating nonclinical, clinical, human abuse potential (HAP), and foreign experience data. Each DAPA includes a formal EightFactor Analysis, along with a clear rationale and recommendation for scheduling, aligned with regulatory expectations.

Contact us
  • Services

Frequently Asked Questions

Primarily first-in-human through Phase II, but support can extend into Phase III and registration to ensure clinical pharmacology and abuse-related findings are consistently interpreted.
Focus is on the quantitative and mechanistic aspects of the drug (PK, PD, exposure–response, DDIs, special populations), with explicit attention to CNS effects and abuse-related considerations that may influence dose selection, safety monitoring, and labeling.
Yes. Engagements often involve independent review and refinement of CRO-drafted protocols, SAPs, and analyses to align them with CNS and regulatory expectations.
Prioritization is based on mechanism of action, metabolic pathways, concomitant medication patterns, and specific regulatory guidance for the therapeutic area and region.
Altreos provides strategic input on exposure–response and PK/PD interpretation and can collaborate with sponsor or external modeling teams; it does not function as a stand-alone pharmacometric service.

Typical outputs include study concepts, protocol text and reviews, SAP input, structured comments on draft reports, and consolidated clinical pharmacology sections for regulatory submissions.

Contact us